Impressive advances have been made in the treatment and management of HIV-1 infected individuals. Combination antiretroviral therapy (cART) has turned HIV-1 infection from an almost invariable deadly infectious disease, to a lifelong manageable infectious disease. However, a cure or vaccine has not been forthcoming. A major problem in HIV-1 infection is the persistent and latently infected cellular and tissue reservoirs. One of these reservoirs is the Gut Associated Lymphoid tissue (GALT), which has been the research focus of our group. Our group and others have shown that HIV-1 evolves differently in different parts of the gastro intestinal tract, which also appears to affect the development of antiretroviral drug resistance. The GALT is not the only reservoir. HIV-1 continues to persist and evolve in various other cell and tissue reservoirs despite intense and apparent successful antiretroviral therapy. Moreover, drug resistance mutations remain prevalent under therapy and successful viral suppression. In addition to finding a vaccine, the research on combating and eradicating the HIV-1 viral reservoirs has also been an important focus of HIV-1 cure strategies. We will discuss some of the research findings on reservoirs in the context of some of the HIV-1 cure approaches.

在HIV-1感染者的治疗和管理方面取得了令人印象深刻的进步。联合抗逆转录病毒疗法（cART）已使HIV-1感染从几乎一成不变的致命传染病变成了终生可管理的传染病。但是，尚未出现治愈或疫苗的方法。HIV-1感染的主要问题是持续和潜在感染的细胞和组织储库。这些储库之一是肠道相关淋巴组织（GALT），它一直是我们小组的研究重点。我们的小组和其他小组已经表明，HIV-1在胃肠道的不同部位发生不同的进化，这似乎也影响了抗逆转录病毒药物耐药性的发展。GALT并不是唯一的水库。尽管进行了强烈而明显的成功的抗逆转录病毒治疗，HIV-1仍继续在各种其他细胞和组织储库中继续发展。此外，在治疗和成功的病毒抑制下，耐药性突变仍然很普遍。除了寻找疫苗以外，抗击和消除HIV-1病毒库的研究也一直是HIV-1治愈策略的重要重点。我们将在某些HIV-1治愈方法的背景下讨论有关储层的一些研究结果。